Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04796285 · ClinicalTrials.gov registry record · NA

A Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor

A NA study of Sepsis and Infectious Disease, sponsored by Brigham and Women's Hospital.

Active
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT04796285: Active NA study of Sepsis and Infectious Disease, sponsored by Brigham and Women's Hospital.

NCT04796285 is a NA study of Sepsis and Infectious Disease that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 6 participants, below the 6,565-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04796285, a NA study of Sepsis and Infectious Disease, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The overall purpose of this study is to demonstrate the usability of a clinical-grade device in the form of a finger clasp similar to a pulse oximeter for monitoring lactate values, by comparing its performance in reading interstitial fluid lactate values against a known clinical standard in the form of venous lactate levels. Serum lactate measurements are used clinically as a measure of end-organ dysfunction and physiologic stress. Changes in lactate may indicate worsening infection in the setting of sepsis, drug toxicity for certain xenobiotics, or exercise tolerance in exercise physiology. Serum lactate cutoffs have been developed for various disease states and trigger a variety of medical decisions directed at managing the course of the disease. A common theme in the application of lactate measurements to understanding changes in physiology is the need to obtain venous blood to determine lactate. While point-of-care assays have been developed that improve the processing speed, there continues to be a need to obtain fingerstick blood or in most cases, venous blood. Obtaining venous blood for serum lactate requires an individual with phlebotomy skills, the processing capabilities of a laboratory to determine lactate concentrations, or the availability of point of care technology. An alternative method to measure lactate is to sample interstitial fluid which surrounds cells and tissues in the body. Obtaining interstitial fluid is potentially less invasive without the need for repeat phlebotomy or the presence of an indwelling intravenous catheter which can become complicated by infection. The analysis of interstitial fluid for glucose has been validated and is clinically utilized in continuous glucose monitors in individuals with diabetes. In this investigation, the investigators will utilize a novel device, the Lab Clasp to obtain interstitial fluid in a noninvasive method. The Lab Clasp is manufactured to resemble a finger pulse oximeter with additional onboar

Primary Outcome

The primary outcome measure will be the average difference in lactate values between the Lab Clasp device and the reference (laboratory venous lactate) in healthy volunteers. We will obtain multiple (nine timepoints in total) investigational-reference measurement pairs in each subject (150 minutes total) and will average the difference over all pairs from all subjects.

Interventions

  • DEVICE Lab Clasp

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2022-08-01
Est. Completion 2026-08
Phase NA
Brigham and Women's Hospital

937 total trials

What the registry record for NCT04796285 still lists

NCT04796285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 6,565-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower).

The record links to 4 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Lab Clasp is the first listed.

NCT04796285 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04796285 about?

NCT04796285 is a clinical study titled "A Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor". The overall purpose of this study is to demonstrate the usability of a clinical-grade device in the form of a finger clasp similar to a pulse oximeter for monitoring lactate values, by comparing its performance in reading interstitial fluid lactate values against a known clinical standard in the for...

What is the current status of trial NCT04796285?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2022-08-01. Estimated completion is 2026-08.

What conditions does trial NCT04796285 study?

This clinical trial studies the following conditions: Sepsis, Infectious Disease, Lactate Blood Increase, Sepsis Bacterial.

What interventions are being tested in trial NCT04796285?

The interventions under investigation include: Lab Clasp (DEVICE).

Who is sponsoring clinical trial NCT04796285?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04796285 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04796285's enrollment target sits among peer trials

6 89th of 90 higher than 2 of 90 other Sepsis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04796285, the US trial registry maintained by the National Library of Medicine. NCT04796285 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.